期刊文献+

外周血CD19^+CD23^+、补体活化产物C5a对川崎病发病及预后的影响 被引量:2

Influence of peripheral blood CD19^+ CD23^+ and complement activation product C5a on pathogenesis and prognosis of Kawasaki disease
下载PDF
导出
摘要 目的通过检测川崎病外周血CD19^+CD23^+、补体活化物C5a的水平,分析其与川崎病发病的关系,为川崎病的治疗提供一定的指导。方法实验组选取2010年5月至2013年5月在西安市儿童医院心血管内科确诊的川崎病患儿30名,根据B超检查进一步分为冠脉扩张组与无冠脉扩张组。对照组选取同一时期无免疫系统疾病及血管炎性疾病患儿30名。在丙种球蛋白使用前后,检测活化的B淋巴细胞CD19^+CD23^+、补体活化产物C5a及外周血抗体IgG、IgA、[gM的水平。结果丙球使用前后,实验组CD19^+CD23^+、C5a含量均高于对照组,存在统计学差异(丙球使用前:t值分别为12.40和14.10,均P<0.05;丙球使用后:t值分别为10.90和11.60,均P<0.05)。丙球使用前,CD19^+CD23^+,C5a在冠脉扩张组与无冠脉扩张组之间存在统计学差异(t值分别为18.78和12.80,均P<0.05);丙球使用后,CD19^+CD23^+、C5a在冠脉扩张组与无冠脉扩张组之间相比也存在统计学差异(t值分别为18.11和10.50,均P<0.05)。结论 B淋巴细胞活化,补体C5a水平增高参与了川崎病的发生,C5a可以作为预测川崎病冠脉损伤的依据。 Objective To detect the levels of peripheral plasma CD 19 +CD23 +and complement activation product C 5a in cases with Kawasaki disease and analyze their relationship with the pathogenesis of Kawasaki disease , so as to provide some guidance for therapy . Methods From May 2010 to May 2013,30 children with Kawasaki disease diagnosed in the department of cardiology in Xi ’an Children’s Hospital were selected in experimental group , and they were further divided into coronary dilatation group and no coronary dilatation group according to B-ultrasonic examinations .Control group included 30 children without immune system disorders or vascular inflammatory disease at the same period.The levels of B lymphocytes CD19 +CD23 +, complement activation product C5a and peripheral blood antibody IgG, IgA, IgM were detected before and after using gammaglobulin .Results The levels of CD19 +CD23 +and complement activation product C5a before and after using gammaglobulin were higher in the experimental group , and the differences were statistically significant (before using gammaglobulin:t value was 12.40 and 14.10, respectively, both P&lt;0.05;after using gammaglobulin:t value was 10.90 and 11.60, respectively, both P〈0.05).There were statistical differences in the levels of CD 19 +CD23 +and complement activation product C5a between coronary dilatation group and no coronary dilatation group before using gammaglobulin ( t value was 18.78 and 12.80, respectively, both P〈0.05), and the differences were still significant between two groups after using gammaglobulin (t value was 18.11 and 10.50, respectively, both P〈0.05).Conclusion B lymphocyte activation and the increasing of complement activation product C 5a participate the pathogenesis of Kawasaki disease , and C5a can be considered as the evidence of predicting coronary injury .
出处 《中国妇幼健康研究》 2014年第2期233-235,共3页 Chinese Journal of Woman and Child Health Research
关键词 川崎病 CDl9+ CD23+ 补体活化C5a 冠脉损伤 kawasaki disease complement activation C5a coronary injury
  • 相关文献

参考文献7

  • 1Gerber M A,Baltimore R S,Eaton C B,et al.Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis A Scientific Statement From the American Heart Association Rheumatic Fever,Endocarditis,and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young,the Interdisciplinary Council on Functional Genomics and Translational Biology,and the Interdisciplinary Council on Quality of Care and Outcomes Research:Endorsed by the American Academy of Pediatrics[J].Circulation,2009,119(11):1541-1551.
  • 2Manlhiot C,Niedra E,McCrindle B W.Long-term management of Kawasaki disease:implications for the adult patient[J].Pediatrics & Neonatology,2013,54(1):12-21.
  • 3邓灵芝,周永勤,黄友敏.川崎病患儿血清中性粒细胞激活肽-78和内脂素水平变化及其意义研究[J].中国全科医学,2011,14(3):283-284. 被引量:5
  • 4Yeung R S M.Kawasaki disease:update on pathogenesis [J].Current Opinion in Rheumatology,2010,22(5):551-560.
  • 5Lee Y C,Kuo H C,Chang J S,et al.Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis [J].Nature genetics,2012,44(5):522-525.
  • 6Wagner E,Frank M M.Therapeutic potential of complement modulation[J].Nature Reviews Drug Discovery,2010,9(1):43-56.
  • 7Park S J,Shin J I.Interleukin-17 and B cell-activating factor in Kawasaki disease and juvenile systemic lupus erythematosus [J].Lupus,2012,21(6):1260.

二级参考文献11

  • 1Mc Crindle BW, Li JS, Minich LL, et al. Coronary artery in volvemen- tin children with kawasaki disease: risk factors from analysis of serial normalized 179. ts [J]. Circulation, 2007, 116 (2): 174-.
  • 2Liu GN, Shi HZ, Xie ZH, et al. Epithelial neutrophil - activating peptide- 78 recruits neutrophils into pleural effusion [ J]. Eur Respir J, 2009, 34 (1): 184-190.
  • 3Zhong M, Tan HW, Gong HP , et al. Increased serum visfatin in pa- tients with metabolic syndrome and carotid a the roscle rusis [ J ]. Clin Endocrinol, 2008, 69 (6): 878-884.
  • 4Frick VO, Rubie C, Wagner M, et al. Enhanced ENA - 78 and IL - 8 expression in patients with malignant pancreatic diseases [ J ]. Pancre- atology, 2008, 8 (4/5): 488-497.
  • 5Bersinger NA, Frischknecht F, Taylor RN, et al. Basal and cytokine -stimulated production of epithelial neutrophil activating peptide -78 ( ENA - 78 ) and interleukin - 8 ( IL - 8 ) by cultured human endometfi- al epithelial and stromal cells [ J ]. Fertil Steril, 2008, 89 ( 5 Sup- pl) : 1530 - 1536.
  • 6Lim SY, Davidson SM, Paramanathan A J, et al. The novel adipocyto- kine visfatin exerts direct cardioprotective effects [ J]. J Mol Med, 2008, 12 (4): 1395-1403.
  • 7Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP - 2/9 production via MAPK and PI3K/Akt signaling pathways: novel insights into visfatin induced angiogenesis [J]. Cadiu- vascRes, 2008, 78 (2): 356-365.
  • 8Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM -1 and VCAM - 1 expression through ROS dependent NF - kappa B activation in endothelial cells [J]. Biochim Biophys Acta, 2008, 1783 (5) : 886 - 895.
  • 9胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2002:632-636.
  • 10无,赵晓东(整理),杜忠东(整理).川崎病专题讨论会纪要[J].中华儿科杂志,2007,45(11):826-830. 被引量:149

共引文献4

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部